OnPoint Oncology
OnPoint Oncology develops subscription-based market access and reimbursement intelligence products for U.S. biotech and pharmaceutical manufacturers in the oncology space, anchored by its focalPoint clearinghouse-level data platform and complemented by intelliPoint market research, assistPoint, and the Buy and Bill Guide. The company operates as a division of RXVantage from Hudson, Ohio.
- Company typePrivate
- Founded2008
- HeadquartersHudson, United States
- Headcount1–10
- GTM typeB2B
- OfferingSoftware
What OnPoint Oncology does
OnPoint Oncology, Inc., founded in 2008 by Tracy L. Lewis and headquartered in Hudson, Ohio, is a private Delaware-incorporated company that operates as a division of RXVantage. The company develops subscription-based market access and reimbursement intelligence products targeting the U.S. oncology market. Its flagship product, focalPoint, is a real-time, web-based data tool that tracks denials, payer policies, and payments at the clearinghouse level, enabling biotech and pharmaceutical manufacturers to identify challenges and opportunities in oncology drug reimbursement. The platform accrues claims data at the clearinghouse level for true match of inbound and outbound claims, and can track products with miscellaneous J-codes without algorithmic estimation, providing diagnosis-level detail.
The company complements focalPoint with three additional products: intelliPoint, a market research platform leveraging a proprietary panel of hematology/oncology physicians, practice administrators, and payers; assistPoint, which supports patient assistance and connectivity through oncology practices; and the Buy and Bill Guide, a self-service subscription educational resource for oncology practices covering coding, claim submissions, denials, and appeals. Underlying technology consists of a proprietary access and reimbursement database with clearinghouse-level data aggregation and real-time analytics, developed and refined over 17+ years by a small (1-10 employee) team.
OnPoint primarily targets enterprise biotech and pharmaceutical manufacturers via field sales, with secondary distribution to oncology practices and clinics. Revenue is generated through recurring annual subscriptions to focalPoint and intelliPoint (enterprise pricing not publicly disclosed) and self-serve subscriptions to the Buy and Bill Guide. The company's leadership draws heavily from oncology industry veterans, including Principal Roberta L. Buell, a nationally recognized oncology reimbursement expert with 23 years of experience presenting over 600 reimbursement seminars and publishing a monthly newsletter read by 4,700 subscribers. OnPoint operates without disclosed outside funding and within a tight geographic and operational footprint.
OnPoint Oncology firmographics
Firmographics- Name
- OnPoint Oncology
- Legal name
- onPoint Oncology, Inc.
- Website
- https://onpointoncology.com
- Company type
- Private
- Founded year
- 2008
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- OnPoint Oncology develops subscription-based market access and reimbursement intelligence products for U.S. biotech and pharmaceutical manufacturers in the oncology space, anchored by its focalPoint clearinghouse-level data platform and complemented by intelliPoint market research, assistPoint, and the Buy and Bill Guide. The company operates as a division of RXVantage from Hudson, Ohio.
- Ownership category
- akta.pro rank
OnPoint Oncology industry classification
Industry- Product category
- Oncology Reimbursement Intelligence
- NAICS
- Software Publishers (513210)
- SIC
- Services-Prepackaged Software (7372)
- akta.pro primary industry
- Oncology Pathways & Precision Medicine Decision Support (HLACAGAH)
- akta.pro secondary industry
- Patient Financial Engagement (Estimates, Billing Presentment, Payments) (HLACAEAI)
Keywords
Where OnPoint Oncology is headquartered
LocationHeadquarters
- HQ city
- Hudson
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
OnPoint Oncology business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Personnel, Technology or R&D, Marketing or Sales, Operations, Others
Revenue model
- focalPoint Subscription: Real-time web-based subscription tool providing around-the-clock insight to denials, payer policy, and payments for provider-administered oncology products. Provides reimbursement intelligence with expert support and market access strategy guidance.
- Buy and Bill Guide: Comprehensive educational guide subscription providing ongoing buy-and-bill education and up-to-date reimbursement information via a website. Includes coding, billing, denials, appeals, Medicare and commercial payer guidance.
- intelliPoint Market Research: Qualitative and quantitative market research services with targeted, product-specific reporting. Includes War Room analysis for new drug launches and actionable reimbursement guides for pharmaceutical companies.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Subscription | Annual | Enterprise subscription plans for pharmaceutical manufacturers |
Go-to-market motion1 record
Distribution channels2 records
Marketing channels4 records
OnPoint Oncology product offering
Product offeringCore offering
OnPoint Oncology develops and sells subscription-based software and data services that help biotech and pharmaceutical manufacturers, as well as oncology practices, navigate buy-and-bill oncology reimbursement. Its flagship product, focalPoint, provides real-time, web-based clearinghouse-level reimbursement intelligence on denials, payer policy, and payments for provider-administered oncology products, complemented by intelliPoint market research panels and the Buy and Bill Guide educational subscription.
Product overview
OnPoint Oncology offers a suite of specialized solutions for the oncology market, anchored by the core focalPoint platform—a real-time reimbursement intelligence tool. The portfolio includes the Buy and Bill Guide for educational content on medication acquisition and billing processes, and intelliPoint for qualitative and quantitative market research. These products work together to address access challenges for providers, patients, and life sciences companies in the complex oncology reimbursement landscape.
Differentiator
Problem solved
Functional benefit
Brands
- focalPoint: A distinctive product that accrues data at the clearing house level for a true match of inbound and outbound claims. Changes the way Biotech/Pharmaceutical manufacturers approach access and reimbursement by identifying opportunities and challenges with real-time data.
- Buy and Bill Guide
- intelliPoint
Products and services
- focalPoint Real-time, web-based reimbursement intelligence platform that aggregates data at the clearinghouse level to match inbound and outbound claims without algorithms, tracks miscellaneous J-code oncology products, and provides diagnosis-level detail on denials, payer policies, and payments for provider-administered oncology products. Sold by subscription to biotech and pharmaceutical manufacturers to support market access, payer marketing, and field sales teams.
- intelliPoint Market research service that provides intelligence-driven qualitative and quantitative research through a proprietary panel of influential hematology/oncology physicians, practice administrators, and payers, with targeted product-specific reporting, War Room analysis for new drug launches, and actionable reimbursement guides. Sold by subscription to life sciences companies and Hem/Onc brands.
- Buy and Bill Guide
Quantifiable outcome
- Consistently reduced time to payment and denial rates for supported products
- +1 more outcomes
Companies that use OnPoint Oncology
Customer profileNamed customers4 records
Segments3 records
Ideal customer profiles2 records
OnPoint Oncology technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
OnPoint Oncology partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- RXVantagecoreRXVantage is the parent company of onPoint Oncology. onPoint Oncology operates as a division of RXVantage, leveraging shared technology platforms and organizational resources.
Scale indicators2 records
Recent moves7 records
Expansion highlights4 records
OnPoint Oncology competitors and assessment
Company assessmentBroad incumbents
- IQVIA: IQVIA is the dominant healthcare data and analytics incumbent serving pharma with commercial effectiveness, market access, and real-world evidence solutions across all therapeutic areas including oncology.
- Cencora (formerly AmerisourceBergen): Cencora operates specialty pharmaceutical distribution and data services (including legacy ION Solutions and Oncology Supply) — closely tied to buy-and-bill oncology reimbursement workflows and overlapping with onPoint's provider and pharma audiences.
- Syneos Health: Syneos Health provides commercial and clinical services to pharma including market access and patient access support — adjacent to onPoint's pharma commercialization intelligence but with a broader service portfolio.
- McKesson (US Oncology Network): McKesson operates the US Oncology Network and specialty distribution services for community oncology practices, including buy-and-bill workflow tools and manufacturer-facing analytics that overlap with onPoint's provider and pharma offerings.
- Premier Inc. (PINC AI): Premier's PINC AI platform provides healthcare supply chain and clinical analytics; its specialty pharmacy and oncology benchmarking capabilities partially overlap with reimbursement and access analytics sold to pharma manufacturers.
Direct peers
- MMIT (Managed Markets Insight & Technology): MMIT provides payer policy, formulary, and reimbursement intelligence to pharma manufacturers — directly overlapping focalPoint's core value proposition in market access data and coverage analytics. Both serve pharma access and reimbursement teams in oncology and specialty therapeutics.
- ZS Associates: ZS Associates operates a large pharma access and launch excellence practice with proprietary data assets serving oncology brand commercialization, including reimbursement strategy consulting and analytics for buy-and-bill products.
- Integra Connect: Integra Connect provides oncology practice management software, data analytics, and value-based care services to oncology practices and pharma manufacturers — overlapping with onPoint's provider-side buy-and-bill education and pharma intelligence offerings.
Emerging players
- Flatiron Health: Flatiron Health is an oncology-specific EHR and real-world data company serving both academic research and pharma commercial use cases, providing overlapping oncology data infrastructure for life sciences customers.
- ConcertAI: ConcertAI focuses on oncology real-world evidence and AI-driven clinical and commercial analytics for pharma and providers, partially overlapping with intelliPoint's market research and access strategy offerings.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat5 records
Key risks5 records
Key highlights6 records
Customer concentration
OnPoint Oncology social profiles
Digital presenceOnPoint Oncology financial estimates
Financial estimateRevenue estimate
Valuation estimate
OnPoint Oncology leadership team
Management profileNumber of profiles
Profiles5 records
OnPoint Oncology funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
OnPoint Oncology M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about OnPoint Oncology
What does OnPoint Oncology do?
OnPoint Oncology develops and sells subscription-based software and data services that help biotech and pharmaceutical manufacturers, as well as oncology practices, navigate buy-and-bill oncology reimbursement. Its flagship product, focalPoint, provides real-time, web-based clearinghouse-level reimbursement intelligence on denials, payer policy, and payments for provider-administered oncology products, complemented by intelliPoint market research panels and the Buy and Bill Guide educational subscription.
Is OnPoint Oncology a public or private company?
OnPoint Oncology is a private company. It is classified as corporate owned and is currently operating.
When was OnPoint Oncology founded?
OnPoint Oncology was founded in 2008. It employs 1 to 10 people.
Where is OnPoint Oncology based?
OnPoint Oncology is headquartered in Hudson, United States, in the North America region.
How does OnPoint Oncology make money?
Three revenue lines are on record. focalPoint Subscription is the primary driver. The others are buy and Bill Guide and intelliPoint Market Research.
Who are OnPoint Oncology's main competitors?
Broad incumbents on record are IQVIA, Cencora (formerly AmerisourceBergen), Syneos Health, McKesson (US Oncology Network) and Premier Inc. (PINC AI). Direct peers are MMIT (Managed Markets Insight & Technology), ZS Associates and Integra Connect. Emerging players are Flatiron Health and ConcertAI.
Does OnPoint Oncology have an API?
No public API is recorded for OnPoint Oncology.
What industry is OnPoint Oncology in?
OnPoint Oncology's product category is Oncology Reimbursement Intelligence. Its primary akta.pro industry code is HLACAGAH, Oncology Pathways & Precision Medicine Decision Support, with a secondary code of HLACAEAI, Patient Financial Engagement (Estimates, Billing Presentment, Payments). Its NAICS code is 513210 and its SIC code is 7372.